Anti-CD262/DR5/TRAILR2 Monoclonal Antibody for FC, ELISA - O14763

Core Product Specifications and Parameters

Biological Background: TRAILR2 Function and Localization

• TRAILR2, also known as Death receptor 5 (DR5), CD262, or KILLER, is a tumor necrosis factor receptor superfamily member encoded by the TNFRSF10B gene.
• This receptor specifically binds the cytotoxic ligand TNFSF10/TRAIL. Following activation, it recruits the adapter molecule FADD and caspase-8 to assemble the death-inducing signaling complex (DISC), thereby initiating caspase cascade-mediated apoptosis. Related references: PMID:10549288
• TRAILR2 also promotes nuclear factor-kappa-B (NF-κB) activation, linking death receptor signaling to inflammatory and immune responses.
• The protein is essential for endoplasmic reticulum (ER) stress-induced apoptosis, highlighting its role in cellular stress pathways.
• Widely expressed in adult and fetal tissues, with very high expression in multiple tumor cell lines (HeLaS3, K-562, HL-60, SW480, A-549, G-361). Highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus, placenta, testis, esophagus, stomach, and throughout the intestinal tract; not detectable in brain.
• Located predominantly at the cell membrane, functioning as a transmembrane receptor.
• The protein undergoes glycosylation and contains disulfide bonds; alternative splicing generates multiple isoforms, potentially explaining different observed molecular weights.

Experimental Guidance and Technical Tips

• The immunogen corresponds to the extracellular domain (amino acids 56-182), suggesting the antibody is suitable for detecting native cell surface TRAILR2 by flow cytometry.
• For ELISA applications, consider using the antibody as a capture or detection reagent against recombinant TRAILR2 extracellular domain or cell lysates.
• Multiple protein bands (12kDa, 45kDa, 47kDa) may arise from alternative splicing, glycosylation, or proteolytic processing; validate the expected band pattern in the relevant sample system.
• As TRAILR2 is widely expressed, optimize blocking conditions and include appropriate controls to minimize non-specific background.
• There is no cross-reactivity data for species other than human; if using with non-human samples, verify reactivity experimentally.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio serves as a comprehensive procurement partner for IVD raw materials, technical services, and consulting from concept to clinic. This anti-TRAILR2 monoclonal antibody is part of our extensive portfolio of rigorously selected antibodies tailored for apoptosis and oncology research. Supply capabilities include validated antibody pairs, optimized monoclonal and polyclonal antibodies, bulk ancillary reagents, and custom rare target sourcing to support your assay development and manufacturing needs.